Victor A. Levin

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

76h-index22.3kcitations366works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(194), Brain Metastases and Treatment(87), Neuroblastoma Research and Treatments(29), Cancer, Hypoxia, and Metabolism(23), Meningioma and schwannoma management(21)

Publications365 total

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma
Journal of Clinical Oncology·2025Open Access
CTNI-58. UPDATED RESULTS OF PHASE 3 STELLAR TRIAL: EFLORNITHINE IMPROVES OVERALL SURVIVAL AND BLINDED INDEPENDENT CENTRAL REVIEW DETERMINED PROGRESSION FREE SURVIVAL IN PATIENTS WITH RECURRENT WHO 2021 GRADE 3 IDH-MUTANT ASTROCYTOMA
Neuro-Oncology·2025Open Access
Advances in neuro-oncology: contributions of the Asilomar Conference on brain tumor research and therapy
Journal of neurosurgery·2024
LTBK-01. PHASE 3 STELLAR STUDY SHOWS EFLORNITHINE IMPROVES OVERALL SURVIVAL (OS) AND PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH RECURRENT 2021 WHO ASTROCYTOMA, IDH-MUTANT GRADE 3
Neuro-Oncology·2024· 2 citedOpen Access
Inhomogeneous creep equation for viscoelastic materials
E3S Web of Conferences·2023Open Access
Radiographic Response Assessment Strategies for Early-Phase Brain Trials in Complex Tumor Types and Drug Combinations: from Digital “Flipbooks” to Control Systems Theory
Neurotherapeutics·2022· 3 citedOpen Access
УПРАВЛЕНИЕ ДЕТОНАЦИОННЫМ ГОРЕНИЕМ ВОДОРОДНО-ВОЗДУШНОЙ СМЕСИ ПОСРЕДСТВОМ ВНЕСЕНИЯ АРГОНА И ОЗОНА
Доклады Российской академии наук Физика технические науки·2021· 2 cited
Effect of eflornithine on mutation frequency in temozolomide-treated U87MG cells
Oncotarget·2020· 2 citedOpen Access
Blood-Brain Barrier Disruption in Neuro-Oncology: Strategies, Failures, and Challenges to Overcome
Frontiers in Oncology·2020· 67 citedOpen Access
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02
Neuro-Oncology Advances·2020· 22 citedOpen Access
ACTR-41. AN ARGUMENT THAT MORE ADJUVANT TEMOZOLOMIDE THERAPY IS BETTER FOR GLIOMA PATIENTS
Neuro-Oncology·2019Open Access
How far will the Voyager <sup>®</sup> take us?
CNS Oncology·2019· 1 citedOpen Access
Drug discovery in neuro-oncology: challenges in the path forward
Neuro-Oncology·2018· 4 citedOpen Access
Understanding brain penetrance of anticancer drugs
Neuro-Oncology·2018· 30 citedOpen Access
Clinical importance of eflornithine (α-difluoromethylornithine) for the treatment of malignant gliomas
CNS Oncology·2018· 39 citedOpen Access
Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02
Journal of Neuro-Oncology·2017· 30 citedOpen Access
CNS Anticancer Drug Discovery and Development: 2016 conference insights
CNS Oncology·2017· 14 citedOpen Access
Abstract CT136: STELLAR: A phase 3, randomized, open-label study to evaluate the efficacy and safety of eflornithine with lomustine compared to lomustine alone in patients with anaplastic astrocytoma that progress/recur after irradiation and adjuvant temozolomide chemotherapy
Cancer Research·2017
Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab
Journal of Neuro-Oncology·2017· 54 cited
STELLAR: A phase 3, randomized, open-label study of eflornithine with lomustine vs lomustine for patients with first recurrence of anaplastic astrocytoma after RT and adjuvant temozolomide.
Journal of Clinical Oncology·2017
page 1 of 19Next →

Frequent Co-authors

Athanassios P. Kyritsis(10), Michael D. Prados(9), W.K. Alfred Yung(9), Philip H. Gutin(8), Charles B. Wilson(8), Pamela Silver(7), W.K. Alfred Yung(6), William M. Wara(6), Kenneth R. Hess(5), Kurt A. Jaeckle(5), Juàn Fueyo(4), Candelaria Gomez‐Manzano(4), Timothy J. McDonnell(4), Mark R. Gilbert(4), Mary Jo Gleason(3), W. K. Alfred Yung(3), Gregory N. Fuller(3), Moshe Maor(3), Christina A. Meyers(3), Kathleen R. Lamborn(3)